Hemochromatosis - Pipeline Review, H1 2018

May 2018 | 41 pages | ID: H857FADDF79EN
Global Markets Direct

Abstracts

Hemochromatosis - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemochromatosis - Pipeline Review, H1 2018, provides an overview of the Hemochromatosis (Genetic Disorders) pipeline landscape.

Hemochromatosis is an iron disorder in which the body simply loads too much iron. Symptoms include joint pain, abdominal pain, fatigue, weakness, diabetes, liver failure and heart failure. Risk factors include family history, alcoholism, taking dietary supplements with iron or vitamin C and history of diabetes, heart disease, or liver disease.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemochromatosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hemochromatosis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hemochromatosis (Genetic Disorders).
• The pipeline guide reviews pipeline therapeutics for Hemochromatosis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hemochromatosis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hemochromatosis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hemochromatosis (Genetic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hemochromatosis (Genetic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hemochromatosis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hemochromatosis - Overview
Hemochromatosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hemochromatosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hemochromatosis - Companies Involved in Therapeutics Development
Ionis Pharmaceuticals Inc
La Jolla Pharmaceutical Company
Protagonist Therapeutics Inc
Silence Therapeutics Plc
Vifor Pharma AG
Hemochromatosis - Drug Profiles
BBI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Replace Hepcidin for Iron Overload Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONISTMPRSS-6LRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJPC-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-8679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTG-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLN-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIT-2763 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hemochromatosis - Dormant Projects
Hemochromatosis - Product Development Milestones
Featured News & Press Releases
Feb 08, 2018: Vifor Pharma Ferroportin Inhibitor Enters Phase-I Clinical Trial
Dec 18, 2017: La Jolla Announces Initiation of Multicenter, Randomized, Phase II Clinical Study of LJPC-401 in Patients with Hereditary Hemochromatosis
Sep 07, 2016: La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401
Jul 28, 2016: Protagonist Therapeutics Receives SBIR Funding for the Development of Injectable Hepcidin Mimetics for Treatment of Iron Overload Disorders
Oct 19, 2015: La Jolla Pharmaceutical Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload
Aug 11, 2015: La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-401
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hemochromatosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hemochromatosis - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Hemochromatosis - Pipeline by La Jolla Pharmaceutical Company, H1 2018
Hemochromatosis - Pipeline by Protagonist Therapeutics Inc, H1 2018
Hemochromatosis - Pipeline by Silence Therapeutics Plc, H1 2018
Hemochromatosis - Pipeline by Vifor Pharma AG, H1 2018
Hemochromatosis - Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hemochromatosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Ionis Pharmaceuticals Inc
La Jolla Pharmaceutical Company
Protagonist Therapeutics Inc
Silence Therapeutics Plc
Vifor Pharma AG